Tutkimus useista hoitomuodoista biomarkkerivalikoiduilla potilailla, joilla on leikkausvaiheessa IB-III ei-pienisoluinen keuhkosyöpä (NAUTIKA1)
NAUTIKA1: Monikeskus, vaihe II, neoadjuvantti- ja adjuvanttitutkimus useista hoitomuodoista biomarkkerivalikoiduilla potilailla, joilla on leikkausvaiheessa IB-III ei-pienisoluinen keuhkosyöpä
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
Tutkimuksen yleiskatsaus
Tila
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskelupaikat
-
-
California
-
Los Angeles, California, Yhdysvallat, 90095
- University of California Los Angeles - Jonsson Comprehensive Cancer Center
-
Orange, California, Yhdysvallat, 92868
- The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange
-
Sacramento, California, Yhdysvallat, 95817
- UC Davis Comprehensive Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Yhdysvallat, 06511
- Yale Cancer Center
-
-
District of Columbia
-
Washington D.C., District of Columbia, Yhdysvallat, 20007
- MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center)
-
-
Florida
-
Tampa, Florida, Yhdysvallat, 33612
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60611
- Northwestern University
-
DeKalb, Illinois, Yhdysvallat, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Geneva, Illinois, Yhdysvallat, 60134
- Northwestern Medicine Cancer Center Delnor
-
Warrenville, Illinois, Yhdysvallat, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, Yhdysvallat, 48109
- University of Michigan
-
-
Minnesota
-
Rochester, Minnesota, Yhdysvallat, 55905
- Mayo Clinic
-
-
Missouri
-
Columbia, Missouri, Yhdysvallat, 65201
- Ellis Fischel Cancer Center
-
St Louis, Missouri, Yhdysvallat, 63108
- Siteman Cancer Center - Washington University Medical Campus
-
-
New Hampshire
-
Lebanon, New Hampshire, Yhdysvallat, 03756
- Dartmouth Hitchcock Medical Center
-
-
New York
-
New York, New York, Yhdysvallat, 10032
- Columbia University Medical Center
-
New York, New York, Yhdysvallat, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Yhdysvallat, 10016
- Laura and ISAAC Perlmutter Cancer Center at NYU Langone.
-
-
Ohio
-
Columbus, Ohio, Yhdysvallat, 43210
- Ohio State University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Yhdysvallat, 15212
- AHN Cancer Institute ? Allegheny General Hospital
-
-
Tennessee
-
Memphis, Tennessee, Yhdysvallat, 38120
- Baptist Clinical Research Institute
-
-
Texas
-
Houston, Texas, Yhdysvallat, 77030-4008
- University of Texas MD Anderson Cancer Center
-
-
Virginia
-
Fairfax, Virginia, Yhdysvallat, 22031
- Virginia Cancer Specialists (Fairfax) - USOR
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria for Neoadjuvant Therapy:
- Pathologically documented NSCLC:
- Newly diagnosed early-stage NSCLC stages IB, IIA, IIB, IIIA, or selected IIIB (T3N2 only) NSCLC of squamous or non-squamous histology. Staging should be based on the 8th edition of the American Joint Committee on Cancer (AJCC)/Union Internationale Contre le Cancer (UICC) NSCLC staging system
- T4 primary NSCLC will be allowed only on the basis of size. Invasion of the diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodules in a different ipsilateral lobe is not permitted
- All participants will undergo clinical staging using computed tomography (CT) and positron emission tomography (PET) scanning, as well as brain imaging using magnetic resonance imaging (MRI). Invasive mediastinal staging by either mediastinoscopy or endo-bronchial ultrasonography is highly encouraged for participants with radiographically suspected mediastinal nodal disease (i.e., N2) but not mandated if the CT or PET scans showed no evidence of N2 disease
- Molecular testing results from clinical laboratory improvement amendments (CLIA)-certified laboratories and showing at least one of the following abnormalities: ALK fusion, ROS1 fusion, NTRK1/2/3 fusion; BRAF V600 mutation, RET fusion, PD-L1 expression in ≥ 1% tumor cells as determined by Food and Drug Administration (FDA)-approved test, KRAS G12C mutation
- Measurable disease, as defined by RECIST v1.1
- NSCLC must have a solid or subsolid appearance on CT scan and cannot have a purely ground glass opacity appearance. For subsolid lesions, the tumor size (i.e., clinical T stage) should be measured based on the solid component only, exclusive of the ground glass opacity component
- Evaluated by the attending surgeon prior to study enrollment to verify that the primary tumor and any involved lymph nodes are technically completely resectable and verify that the participant is medically operable
- Adequate pulmonary function to be eligible for surgical resection with curative intent
- Adequate cardiac function to be eligible for surgical resection with curative intent
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Adequate hematologic and end-organ function
- Negative hepatitis B surface antigen (HBsAg) test at screening for cohort
- Negative total hepatitits B core antibody (HBcAb) test at screening for cohort, or positive total HBcAb test followed by a negative hepatitis B virus (HBV) deoxyribonucleic acid (DNA) test at screening
- Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV ribonucleic acid (RNA) test at screening
- Male participants must be willing to use acceptable methods of contraception
- Female participants of childbearing potential must agree to use acceptable methods of contraception
Inclusion Criteria for Adjuvant Therapy (TKI Cohorts and KRAS G12C cohort [if continuing on Divarasib]):
- Participants whose tumors lack radiographic progression
- ECOG Performance Status of 0 or 1
- Adequate hematologic and end-organ function
Exclusion Criteria
- NSCLC that is clinically T4 by virtue of mediastinal organ invasion or Stage IIIB by virtue of N3 disease
- Any prior therapy for lung cancer, including chemotherapy, targeted therapy, immunotherapy, or radiotherapy, within 2 years
- Participants with prior lung cancer
- Major surgical procedure within 28 days prior to Cycle 1, Day 1
- Malignancies other than the disease under study within 3 years prior to Cycle 1, Day 1, with the exception of participants with a negligible risk of metastasis or death and with expected curative outcome
- Treatment with an investigational agent for any condition within 4 weeks prior to Cycle 1, Day 1
- Participants known to be positive for human immunodeficiency virus (HIV) are excluded if they meet any of the following criteria: cluster of differentiation 4 (CD4)+ T-cell count of <350 cells/microliters (cells/µL); detectable HIV viral load; history of an opportunistic infection within the past 12 months; on stable antiretroviral therapy for <4 weeks
- Severe infection within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infections, or any active infection that, in the opinion of the investigator, could impact participant safety
- Pregnant or lactating, or intending to become pregnant during the study
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: ALK Cohort (Enrolment Closed)
Participants will receive up to 8 weeks of alectinib neoadjuvant treatment before undergoing surgical resection per standard of care (SOC). All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the adjuvant treatment phase with alectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of alectinib. Enrolment Closed. |
Participants will receive oral alectinib twice per day (BID).
Muut nimet:
Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC. Participants will receive SOC chemotherapy as determined by the treating physician. |
|
Kokeellinen: ROS 1 Cohort (Enrolment Closed)
Participants will receive up to 8 weeks of entrectinib neoadjuvant treatment before undergoing surgical resection per SOC. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the adjuvant treatment phase with entrectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of entrectinib. Enrolment Closed. |
Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC. Participants will receive SOC chemotherapy as determined by the treating physician. Participants will receive oral entrectinib daily.
Muut nimet:
|
|
Kokeellinen: NTRK Cohort (Enrolment Closed)
Participants will receive up to 8 weeks of entrectinib neoadjuvant treatment before undergoing surgical resection per SOC. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the adjuvant treatment phase with entrectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of entrectinib. Enrolment Closed. |
Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC. Participants will receive SOC chemotherapy as determined by the treating physician. Participants will receive oral entrectinib daily.
Muut nimet:
|
|
Kokeellinen: BRAF Cohort (No Participants Enrolled, Cohort Closed)
Participants will receive up to 8 weeks of vemurafenib plus cobimetinib neoadjuvant treatment before undergoing surgical resection per SOC. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the adjuvant treatment phase with vemurafenib plus cobimetinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of of vemurafenib plus cobimetinib. Cohort closed. |
Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC. Participants will receive SOC chemotherapy as determined by the treating physician. Participants will receive oral vemurafenib BID.
Muut nimet:
Participants will receive oral cobimetinib daily.
Muut nimet:
|
|
Kokeellinen: RET Cohort (Cohort closed)
Participants will receive up to 8 weeks of pralsetinib neoadjuvant treatment before undergoing surgical resection per SOC. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the adjuvant treatment phase with pralsetinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of pralsetinib. Cohort closed. |
Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC. Participants will receive SOC chemotherapy as determined by the treating physician. Participants will receive oral pralsetinib daily.
Muut nimet:
|
|
Kokeellinen: PD-L1 Cohort (Enrolment Closed)
Participants with positive programmed death-ligand 1 (PD-L1) in ≥1% tumor cells will receive 4 cycles of atezolizumab neoadjuvant treatment. During neoadjuvant Cycle 1 of atezolizumab, participants will also receive low-dose stereotactic body radiation therapy (SBRT) (8 gray [Gy] X 3). Adjuvant treatment consists of SOC treatment as determined by the investigator, per National Comprehensive Cancer Network (NCCN) guidelines. Enrolment Closed. |
Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC. Atezolizumab will be administered by intravenous (IV) infusion.
Muut nimet:
Participants will receive SBRT given concurrently, starting with the first dose of atezolizumab. |
|
Kokeellinen: KRAS G12C Cohort
Participants will receive up to 8 weeks of divarasib as neoadjuvant treatment before undergoing surgical resection per SOC. PD-L1 negative participants whose tumors have pathological response or lack radiographic progression will be have the option of continuing divarasib alone for up to 3 years or 1-4 cycles of SOC chemotherapy followed by divarasib for 3 years as adjuvant therapy. For participants who test positive PD-L1, they will have the option to receive 1-4 cycles of SOC chemotherapy followed by atezolizumab for up to 16 cycles or SOC alone. |
Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC. Participants will receive SOC chemotherapy as determined by the treating physician. Participants in the KRAS G12C cohort will receive oral divarasib for approximately 8 weeks until the day before surgery as neoadjuvant therapy up to 3 years as adjuvant therapy.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
KRAS G12C Cohort: Percentage of Participants With 3-5 Grade Adverse Events (AEs)
Aikaikkuna: After surgical resection (approximately study Week 8)
|
After surgical resection (approximately study Week 8)
|
|
|
KRAS G12C Cohort: Percentage of Participants Without Delays of Surgery due to Treatment-related AEs as Reported by the Investigator
Aikaikkuna: After surgical resection (approximately study Week 8)
|
After surgical resection (approximately study Week 8)
|
|
|
Tyrosine Kinase Inhibitor (TKI) Cohort: Proportion of Participants With Major Pathologic Response (MPR)
Aikaikkuna: After surgical resection (approximately study Week 8)
|
MPR is defined as ≤ 10% residual viable tumor cells as scored by local pathologists. |
After surgical resection (approximately study Week 8)
|
|
Checkpoint Inhibitor (CPI) Cohort: Pathological Complete Response (pCR)
Aikaikkuna: After surgical resection (approximately study Week 8)
|
Scored by local pathologists; defined as lack of any viable tumor cells on review of hematoxylin and eosin (H&E) slides after complete evaluation of a resected lung cancer specimen including all sampled regional lymph nodes. |
After surgical resection (approximately study Week 8)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Patologinen regressio, joka perustuu painotettuun elinkelpoisten kasvainsolujen prosenttiosuuden arviointiin
Aikaikkuna: Leikkauksen jälkeen (noin tutkimusviikko 8)
|
Leikkauksen jälkeen (noin tutkimusviikko 8)
|
|
|
Tutkijan arvioima vasteen tavoitevasteprosentti (ORR) vasteen arviointikriteereitä kohti kiinteiden kasvainten versiossa 1.1 (RECIST v1.1)
Aikaikkuna: Neoadjuvanttihoidon jälkeen (noin tutkimusviikon 8 jälkeen)
|
Neoadjuvanttihoidon jälkeen (noin tutkimusviikon 8 jälkeen)
|
|
|
Tautiton selviytyminen (DFS)
Aikaikkuna: Ensimmäisestä taudin puuttumisesta paikalliseen tai etäiseen uusiutumiseen tai kuolemaan mistä tahansa syystä, sen mukaan, kumpi tapahtuu ensin, tutkimuksen loppuun asti (enintään 9 vuotta)
|
Ensimmäisestä taudin puuttumisesta paikalliseen tai etäiseen uusiutumiseen tai kuolemaan mistä tahansa syystä, sen mukaan, kumpi tapahtuu ensin, tutkimuksen loppuun asti (enintään 9 vuotta)
|
|
|
Tapahtumaton selviytyminen (EFS)
Aikaikkuna: Ensimmäisestä tutkimushoidon annoksesta ensimmäiseen dokumentoituun taudin etenemiseen RECIST v1.1:n mukaan tai paikalliseen tai etäiseen taudin uusiutumiseen tutkijan määrittämänä tai kuolemaan mistä tahansa syystä sen mukaan, kumpi tapahtuu ensin, tutkimuksen loppuun asti (enintään 9 vuotta)
|
Ensimmäisestä tutkimushoidon annoksesta ensimmäiseen dokumentoituun taudin etenemiseen RECIST v1.1:n mukaan tai paikalliseen tai etäiseen taudin uusiutumiseen tutkijan määrittämänä tai kuolemaan mistä tahansa syystä sen mukaan, kumpi tapahtuu ensin, tutkimuksen loppuun asti (enintään 9 vuotta)
|
|
|
Kokonaiseloonjääminen (OS)
Aikaikkuna: Ensimmäisestä tutkimuslääkityksen annoksesta mistä tahansa syystä johtuvaan kuolemaan tutkimuksen loppuun asti (enintään 9 vuotta)
|
Ensimmäisestä tutkimuslääkityksen annoksesta mistä tahansa syystä johtuvaan kuolemaan tutkimuksen loppuun asti (enintään 9 vuotta)
|
|
|
Kiertävän kasvaimen DNA:n (ctDNA) puhdistumanopeus
Aikaikkuna: Ennen leikkausta (ennen tutkimusta viikkoa 8)
|
Ennen leikkausta (ennen tutkimusta viikkoa 8)
|
|
|
Percentage of Participants With AEs
Aikaikkuna: Up to 9 years
|
Up to 9 years
|
|
|
Proportion of Participants With MPR
Aikaikkuna: After surgical resection (approximately study Week 8)
|
Defined as ≤10% residual viable tumor cells) based on surgical resection as defined by Hellmann et al. (2014) and Travis et al. (2020). TKI cohorts: MPR will be scored by a central pathology committee consensus read. CPI cohort: MPR will be scored by local pathologists and central pathology committee consensus read. KRAS G12C cohort: MPR will be scored by local pathologists and central pathology committee consensus read. |
After surgical resection (approximately study Week 8)
|
|
Proportion of Participants With pCR
Aikaikkuna: After surgical resection (approximately study Week 8)
|
Defined as lack of any viable tumor cells on review of H&E slides after complete evaluation of a resected lung cancer specimen, including all sampled regional lymph nodes. TKI cohorts: pCR will be scored by local pathologists and a central pathology committee consensus read. CPI cohort: pCR will be scored by a central pathology committee consensus read. KRAS G12C cohort: pCR will be scored by a central pathology committee consensus read. |
After surgical resection (approximately study Week 8)
|
|
Nodal Downstaging
Aikaikkuna: After surgical resection (approximately study Week 8)
|
Defined as percentage of participants with reduced stages in regional lymph nodes at surgery. |
After surgical resection (approximately study Week 8)
|
|
KRAS G12C Cohort: Plasma Concentration of Divarasib at Specified Timepoints
Aikaikkuna: Neo-adjuvant: pre-dose & 2 hours post-dose on Day 1 of Cycles 1 & 2; Pre-surgery (before Week 8): pre-dose; Adjuvant treatment: pre-dose & 2 hours post-dose on Day 1 of Cycles 1-6, pre-dose on Day 1 of Cycle 9 (each cycle=28 days);
|
|
Neo-adjuvant: pre-dose & 2 hours post-dose on Day 1 of Cycles 1 & 2; Pre-surgery (before Week 8): pre-dose; Adjuvant treatment: pre-dose & 2 hours post-dose on Day 1 of Cycles 1-6, pre-dose on Day 1 of Cycle 9 (each cycle=28 days);
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Clinical Trials, Hoffmann-La Roche
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Neoplasmat sivustoittain
- Neoplasmat
- Hengityselinten sairaudet
- Keuhkosairaudet
- Hengitysteiden kasvaimet
- Rintakehän kasvaimet
- Keuhkojen kasvaimet
- Syöpä, bronkogeeninen
- Keuhkoputkien kasvaimet
- Karsinooma, ei-pienisoluinen keuhko
- Rikkiyhdisteet
- Orgaaniset kemikaalit
- Heterosykliset yhdisteet
- Heterosykliset yhdisteet, 2-rengas
- Heterosykliset yhdisteet, sulatettu rengas
- Terapeuttiset lääkkeet
- Amidit
- Indolit
- Sulfonamidit
- Sulakkeet
- Vemurafenibi
- Lääkehoito
- söpö
- kobimetiini
- entrektinibi
- alektini
- pralsetinibi
Muut tutkimustunnusnumerot
- ML41591
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .